Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.67 |
| ▸ | CES1 | P23141 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7611173 | 1.00 | CES2 (0.67) | CES2CES1LMNAMAPK1SRC | |
| SCHEMBL1174028 | 1.00 | CES2 (0.67) | CES2CES1LMNAMAPK1SRC | |
| Benzene SCHEMBL28201061 | 0.82 | CES2 (0.76) | CES2CES1LMNAMAPK1SRC | |
| SCHEMBL604040 | 0.82 | CES2 (0.76) | CES2CES1LMNAMAPK1SRC | |
| SCHEMBL234580 | 0.82 | CES2 (0.76) | CES2CES1LMNAMAPK1SRC | |
| SCHEMBL5899350 | 0.82 | CES2 (0.76) | CES2CES1LMNAMAPK1SRC | |
| Ammonia Solution, Strong SCHEMBL38660268 | 0.80 | CES2 (0.73) | CES2CES1LMNAMAPK1SRC | |
| Hydrochloric Acid SCHEMBL7037834 | 0.80 | CES2 (0.73) | CES2CES1LMNAMAPK1SRC | |
| SCHEMBL5820145 | 0.80 | CES2 (0.73) | CES2CES1LMNAMAPK1SRC | |
| Methane SCHEMBL6115781 | 0.80 | CES2 (0.73) | CES2CES1LMNAMAPK1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020086863-A1 | New arylglycinamide derivatives, processes for the manufacture thereof and pharmaceutical compositions containing these compounds | BOEHRINGER INGELHEIM KG. | 2002-07-04 | — | — | US | disclosed |
| US-6413959-B1 | NEUROKININ(TACHYKININ) ANTAGONISTS | BOEHRINGER INGELHEIM KG (DE) | 2002-07-02 | — | — | US | disclosed |
| US-6303601-B2 | NEUROKININ (TACHYKININ)-ANTAGONISTS; FOR THERAPY OF COLLAGENOSIS, DYSFUNCTION OF THE URINARY TRACT, HEMORRHOIDS, NAUSEA, VOMITING, PAIN, INFLAMMATORY DISEASE OF RESPIRATORY TRACT, ALLERGIC DISEASE OF RESPIRATORY TRACT | BOEHRINGER INGELHEIM KG (DE) | 2001-10-16 | — | — | US | disclosed |
| US-6294556-B1 | NEUROKININ (TACHYKININ)-ANTAGONISTS. SUBSTANCE P-ANTAGONISM AND ALSO NEUROKININ A- OR NEUROKININ B-ANTAGONISTIC PROPERTIES. THEY ARE USEFUL FOR SUBSTANCE P-ANTAGONISM AND ALSO NEUROKININ A- OR NEUROKININ B-ANTAGONISTIC PROPERTIES. | BOEHRINGER INGELHEIM KG (DE) | 2001-09-25 | — | — | US | disclosed |
| US-20010011093-A1 | Arylgycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds | SCHNORRENBERG GERD (DE) | 2001-08-02 | — | — | US | disclosed |
| US-6251909-B1 | Arylglycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds | BOEHRINGER INGELHEIM KG (DE) | 2001-06-26 | — | — | US | disclosed |
| US-6124296-A | NEUROKININ (TACHYKININ) ANTAGONISTS | BOEHRINGER INGELHEIM KG (DE) | 2000-09-26 | — | — | US | disclosed |
| US-6121262-A | NEUROKIN (TACHYKININ) ANTAGONISTS | BOEHRINGER INGELHEIM KG (DE) | 2000-09-19 | — | — | US | disclosed |
| US-5861509-A | NEUROKININ AND TACHYKININ ANTAGONISTS; RESPIRATORY SYSTEM DISORDERS, ANTIINFLAMMATORY AGENTS | BOEHRINGER INGELHEIM KG (DE) | 1999-01-19 | — | — | US | disclosed |
| US-5710155-A | NEUROKIN ANTAGONISTS USEFUL IN TREATMENT OF RESPIRATORY, INFLAMMATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM KG (DE) | 1998-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011093-A1 | Arylgycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds | NPY2R, HRH2, CNR2 | CES2 689/4885CES1 2546/4885LMNA 2861/4885 |
| US-20020086863-A1 | New arylglycinamide derivatives, processes for the manufacture thereof and pharmaceutical compositions containing these compounds | GCGR, CCKAR, GALR2 | CES2 857/4885CES1 2299/4885LMNA 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.